A first-in-human study of conatumumab in adult patients with advanced solid tumors.

PURPOSE To determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of conatumumab, an investigational, fully human monoclonal agonist antibody against human death receptor 5, in patients with advanced solid tumors. EXPERIMENTAL DESIGN In the dose-escalation phase, patients received escalating intravenous doses of conatumumab… CONTINUE READING